Impact of age on outcomes with PD-(L)1 blockade in patients (Pts) with non-small cell lung cancer (NSCLC).

• DOI: 10.1200/jco.2018.36.15_suppl.10040
• Publication Date: 2018-09-05T14:49:33Z
• Authors: Morgan Lichtenstein; Ryan David Nipp; Kelly Goodwin; Danyon Anderson; Richard Newcomb; Justin F. Gainor
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

10040 Background: As the population ages, it has become increasingly important to understand risks and benefits of novel agents among older adults with cancer. Immunotherapy (IO) revolutionized treatment advanced NSCLC, but less is known about activity PD-(L)1 blockade in (≥70 years). In these pts, immunosenescence may theoretically blunt effectiveness anti-PD-(L)1 therapy and/or alter its toxicity profile. We sought assess impact age on clinical outcomes rates IO-related toxicities pts NSCLC treated anti-PD-(L)1. Methods: retrospectively evaluated all at our institution IO between 1/2013 10/2017. To progression-free survival (PFS) overall (OS) across groups, we performed Kaplan-Meier Cox regression models adjusted for sex, ECOG, comorbidity, stage diagnosis (dx), time since dx metastatic disease, lines prior IO. toxicities, steroid use, hospitalizations were also compared. Results: Of 245 141 (58%) < 70 years 104 (42%) ≥70 old. Compared younger had higher comorbidity scores (6.9 vs 6.6, p = 0.024), worse ECOG (1.4 1.2, 0.011), lower (stage 4: 50% 75%, 0.001). Older similar median PFS (2.6 2.0 months, 0.14) blockade; multivariable demonstrated equivalent groups (HR: 0.81, 0.19). a OS (8.6 14 0.10). After adjusting key confounders, however, no significant difference by (HR 1.4 0.070). Overall, 102 experienced IO-toxicities (41% 44%, 0.69). Thyroiditis (17%), pneumonitis (10%), dermatitis (9%) most common. Toxicity-associated use (26% 25%, 1.0) (12% 10%, 0.68) did not differ groups. Conclusions: compared receiving blockade, suggesting that be viable option geriatric population.